Interview with the Founder and CSO of Equaly, Jean-Marie Saint-Remy and CEO François Boitquin

The Founder and CSO of Equaly, Jean-Marie Saint-Remy, is sharing his ground-breaking discovery regarding the potential of the innate immune system to address various disorders. Founded in 2020, Equaly aims to develop a platform that harnesses this potential by activating natural killer T (NKT) cells specifically designed to recognize and respond to cancer-related antigens, such as those associated with TP53 mutations, which are present in over 60% of human cancers. Their innovative approach enables the creation of cost-effective, off-the-shelf therapies with minimal risk of off-target effects, making them adaptable for different patients with the same detected mutated transcription factor.

Read the Bioneex Story with Equaly